norketotifen / Emergo Therap - LARVOL DELTA

Efficacy and Safety of Norketotifen in Uncomplicated Influenza-like Illness (clinicaltrials.gov) - P2b | N=315 | Completed | Sponsor: Emergo Therapeutics, Inc. | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Respiratory Diseases

Efficacy and Safety of Norketotifen in Uncomplicated Influenza-like Illness (clinicaltrials.gov) - P2b; N=320; Active, not recruiting; Sponsor: Emergo Therapeutics, Inc.; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Infectious Disease • Respiratory Diseases

Efficacy and Safety of Norketotifen in Uncomplicated Influenza-like Illness (clinicaltrials.gov) - P2b; N=320; Recruiting; Sponsor: Emergo Therapeutics, Inc.; Trial completion date: May 2021 ➔ Nov 2021; Trial primary completion date: Apr 2021 ➔ Oct 2021

Clinical • Trial completion date • Trial primary completion date • Infectious Disease • Respiratory Diseases

Efficacy and Safety of Norketotifen in Uncomplicated Influenza-like Illness (clinicaltrials.gov) - P2b; N=320; Recruiting; Sponsor: Emergo Therapeutics, Inc.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease • Respiratory Diseases

Efficacy and Safety of Norketotifen in Uncomplicated Influenza-like Illness (clinicaltrials.gov) - P2b; N=320; Not yet recruiting; Sponsor: Emergo Therapeutics, Inc.

Clinical • New P2b trial • Infectious Disease

Norketotifen for the Treatment of Uncomplicated Influenza-like Illness (clinicaltrials.gov) - P2b; N=238; Completed; Sponsor: Emergo Therapeutics, Inc.; Recruiting ➔ Completed

Clinical • Trial completion • Infectious Disease

Norketotifen for the Treatment of Uncomplicated Influenza-like Illness (clinicaltrials.gov) - P2b; N=242; Recruiting; Sponsor: Emergo Therapeutics, Inc.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open